{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -4.237284, "regularMarketPrice": 2.26, "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "exchange": "FRA", "shortName": "ARBUTUS BIOPHARMA", "longName": "Arbutus Biopharma Corporation", "messageBoardId": "finmb_34160168", "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "firstTradeDateMilliseconds": 1389164400000, "priceHint": 4, "regularMarketChange": -0.099999905, "regularMarketTime": 1683880030, "regularMarketDayHigh": 2.32, "regularMarketDayRange": "2.26 - 2.32", "regularMarketDayLow": 2.26, "regularMarketVolume": 4500, "regularMarketPreviousClose": 2.36, "bid": 2.315, "ask": 2.34, "bidSize": 1000, "askSize": 1000, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 2.29, "averageDailyVolume3Month": 169, "averageDailyVolume10Day": 140, "fiftyTwoWeekLowChange": 0.3564, "fiftyTwoWeekLowChangePercent": 0.18722421, "fiftyTwoWeekRange": "1.9036 - 2.935", "fiftyTwoWeekHighChange": -0.67499995, "fiftyTwoWeekHighChangePercent": -0.22998296, "fiftyTwoWeekLow": 1.9036, "fiftyTwoWeekHigh": 2.935, "earningsTimestamp": 1683204300, "earningsTimestampStart": 1690975800, "earningsTimestampEnd": 1691407800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.43, "epsForward": -0.79, "epsCurrentYear": -0.9, "priceEpsCurrentYear": -2.5111113, "sharesOutstanding": 166134000, "bookValue": 0.872, "fiftyDayAverage": 2.58075, "fiftyDayAverageChange": -0.32075, "fiftyDayAverageChangePercent": -0.12428558, "twoHundredDayAverage": 2.3844216, "twoHundredDayAverageChange": -0.1244216, "twoHundredDayAverageChangePercent": -0.05218104, "marketCap": 376879840, "forwardPE": -2.8607595, "priceToBook": 2.5917432, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.4 - Buy", "tradeable": false, "cryptoTradeable": false, "symbol": "I9DN.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "701 Veterans Circle", "city": "Warminster", "state": "PA", "zip": "18974", "country": "United States", "phone": "267 469 0914", "fax": "267 282 0411", "website": "https://www.arbutusbio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.", "fullTimeEmployees": 96, "companyOfficers": [{"maxAge": 1, "name": "Mr. William H. Collier", "age": 61, "title": "Pres, CEO & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 933011, "fmt": "933.01k", "longFmt": "933,011"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 145950, "fmt": "145.95k", "longFmt": "145,950"}}, {"maxAge": 1, "name": "Mr. Michael J. McElhaugh", "age": 48, "title": "COO & Chief Bus. Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 606625, "fmt": "606.62k", "longFmt": "606,625"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael J. Sofia Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 628435, "fmt": "628.43k", "longFmt": "628,435"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David C. Hastings CPA", "age": 61, "title": "CFO & Chief Accounting Officer", "yearBorn": 1961, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lisa M. Caperelli", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Elizabeth  Howard J.D., Ph.D.", "age": 68, "title": "Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.", "yearBorn": 1954, "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.", "age": 71, "title": "Sec.", "yearBorn": 1951, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}